Pharmaceuticals

Oral Antidiabetic Drugs Market Insights Highlighting Opportunities Supporting Growth To 2030

May 1, 2026May 6, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Large Will The Oral Antidiabetic Drugs Market Be By 2030 Compared To Its 2026 Market Size?

The oral antidiabetic drugs market has experienced robust expansion in recent years. This market is projected to expand from $66.73 billion in 2025 to $71.42 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 7.0%. Historically, this growth has been influenced by factors such as the limited availability of oral antidiabetic drug classes, a reliance on conventional biguanides and sulfonylureas, the increasing incidence of type 2 diabetes, expanding hospital and pharmacy distribution networks, and rising awareness of diabetes management.

The oral antidiabetic drugs market is anticipated to experience substantial expansion in the coming years. It is projected to attain a valuation of $92.64 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.7%. This growth during the forecast period is attributable to several factors, including the development of novel dpp-4 inhibitors and sglt2 inhibitors, the broadening of combination therapies, a greater embrace of personalized medicine approaches, the proliferation of online pharmacy and telemedicine channels, and increasing government initiatives for diabetes care. Key trends for this period encompass the rising prevalence of type 2 diabetes, an increasing adoption of combination oral antidiabetic drugs, the expansion of online and retail pharmacy channels, a growing emphasis on personalized diabetes management, and enhanced awareness and education on diabetes care.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25854&type=smp

Which Factors Are Influencing The Growth Of The Oral Antidiabetic Drugs Market?

The escalating incidence of type 2 diabetes is anticipated to drive the expansion of the oral antidiabetic drugs market. Type 2 diabetes is defined as a chronic condition where the body either resists insulin or fails to produce enough to maintain normal glucose levels. The increase in type 2 diabetes stems from rising obesity rates, as surplus body fat often results in insulin resistance and impaired glucose regulation. Oral antidiabetic drugs aid in managing type 2 diabetes by improving insulin sensitivity, enhancing insulin secretion, or reducing glucose production and absorption, thereby sustaining optimal blood sugar levels. For instance, in March 2025, the Office for Health Improvement and Disparities, a UK-based government agency, reported that the prevalence of type 2 diabetes in adults aged 17+ in England reached 7.0%, an increase from 6.8% in March 2023. Thus, the growing occurrence of type 2 diabetes is propelling the growth of the oral antidiabetic drugs market.

How Are Different Segments Classified In The Oral Antidiabetic Drugs Market Segment Analysis?

The oral antidiabetic drugs market covered in this report is segmented –

1) By Drug Class: Biguanides, Dipeptidyl Peptidase-4 Inhibitors, Sodium Glucose Transport Protein -2 Inhibitors, Sulfonylureas, Thiazolidinediones, Megalitinides, Alpha Glucosidase Inhibitors, Other Drug Classes

2) By Route Of Administration: Oral, Sublingual, Buccal

3) By Therapeutic Area: Type 2 Diabetes, Gestational Diabetes, Type 1 Diabetes

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Channels

5) By End User: Hospitals, Pharmact Store, Drug Store, Diabetes Treatment Centers, Other End Users

Subsegments:

1) By Biguanides: Metformin Hydrochloride, Metformin Extended Release, Combination Products

2) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin, Vildagliptin

3) By Sodium Glucose Transport Protein-2 (SGLT2) Inhibitors: Canagliflozin, Dapagliflozin, Empagliflozin, Ertugliflozin

4) By Sulfonylureas: Glipizide, Glyburide, Glimepiride, Chlorpropamide, Tolbutamide

5) By Thiazolidinediones: Pioglitazone, Rosiglitazone

6) By Meglitinides: Repaglinide, Nateglinide

7) By Alpha Glucosidase Inhibitors: Acarbose, Miglitol, Voglibose

8) By Other Drug Classes: Bromocriptine, Colesevelam

What Trends Are Transforming The Oral Antidiabetic Drugs Market?

Leading companies in the oral antidiabetic drugs market are prioritizing clinical trials to innovate more potent and secure treatment alternatives, broaden their product ranges, and obtain regulatory clearances for advanced therapies. Clinical trials are structured research investigations carried out on human participants to gauge the safety, efficacy, and adverse effects of new medical interventions, medications, or procedures. As an illustration, in April 2025, Eli Lilly and Company, a US-based pharmaceutical entity, unveiled Orforglipron, a once-daily oral small-molecule GLP-1 receptor agonist developed to simplify diabetes care after completing a successful phase 3 trial. This oral medication seeks to offer comparable effectiveness and safety to injectable choices while simultaneously boosting patient adherence. In clinical studies, orforglipron decreased HbA1c (a measure of blood sugar control) by an average of 1.3% to 1.6% across various dosages over 40 weeks.

Who Are The Companies Driving Activity In The Oral Antidiabetic Drugs Market?

Major companies operating in the oral antidiabetic drugs market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Novo Nordisk A/S, C.H. Boehringer Sohn AG & Co. KG, Viatris Inc., Teva Pharmaceutical Industries Limited, Astellas Pharma Inc., Sun Pharmaceutical Industries Limited, Cipla Limited

Get The Full Oral Antidiabetic Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/oral-antidiabetic-drugs-global-market-report

Which Region Dominates The Oral Antidiabetic Drugs Market By Market Share?

North America was the largest region in the oral antidiabetic drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral antidiabetic drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Oral Antidiabetic Drugs Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/oral-antidiabetic-drugs-global-market-report

Browse Through More Reports Similar to the Global Oral Antidiabetic Drugs Market 2026, By The Business Research Company

Antidiabetics Market Report 2026

https://www.thebusinessresearchcompany.com/report/antidiabetics-global-market-report

Antidiabetics Market Report 2026

https://www.thebusinessresearchcompany.com/report/antidiabetics-global-market-report

Antidiabetics Market Report 2026

https://www.thebusinessresearchcompany.com/report/antidiabetics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795